Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September

Cancer, brain; Cancer, breast
It is in a Phase I MTD study in healthy volunteers for the treatment of metastatic breast cancer, including breast cancer brain metastases (BCBM) (Press release Radius, AUG 28, 2014, View Source [SID:1234501003]). The study is designed to evaluate the tolerability, safety and pharmacokinetics of RAD1901, and also use 18F-fluroestradiol positron emission tomography to provide a pharmacodynamic assessment of estrogen receptor turnover following RAD1901 treatment. Levels of RAD1901 in cerebrospinal fluid samples taken from the study subjects will be measured to confirm that RAD1901 has crossed the blood brain barrier.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!